Immunomedics Lupus Treatment Shows Success - WSJ.com

Links shared publicly online about this topic.

  • 1,793
    total visits

Immunomedics Lupus Treatment Shows Success - WSJ.com

online.wsj.com

UCB and Immunomedics said a mid-stage trial comparing their treatment to placebo for treating lupus over 12 weeks showed meaningful treatment effect.

View full resource at online.wsj.com

Tags: Lupus, UCB

  • Share

Most Recently Shared on August 27, 2009 at 12:21 pm By:

WSJHealth WSJ Health

Immunomedics Lupus Treatment Shows Success http://bit.ly/18jaFQ

3 years ago...

Read the Latest in Lupus Research: Urine May Help Track Kidney Disease and Predict Treatment Success in People With Lupus - BUTTERFLIES AMONG US

lupusbutterflies.ning.com — “Lupus nephritis (LN) -- inflammation of the kidney -- can damage the kidney's ability to remove waste from the body. Currently, the best way to diagnose kidney inflammation is with a biopsy, an invasive procedure that can sometimes have serious side effects. Researchers have been working to develop specific tests that can be done on urine samples. The results of this study showed that levels of mRNA for FOXP3 could potentially become a test that can be done on simple urine samples to help figureView full resource at lupusbutterflies.ning.com

  • View Related
  • Share

Most Recently Shared on March 24, 2010 at 11:48 am By:

UPDATE 3-Immunomedics soars as lupus drug shows promise | Reuters

reuters.com — “* Positive Phase IIb results for UCB, Immunomedics drug * Treatment advantage of epratuzumab vs placebo 24.9 pct * Analysts say result promising but drug still high risk * Immunomedics shares upView full resource at reuters.com

  • View Related
  • Share

Most Recently Shared on August 27, 2009 at 3:44 pm By:

LupusResearch LRI Health Organization

Immunomedics lupus drug shows promise; Positive Phase IIb results for epratuzumab http://ow.ly/lyNt

3 years ago...

UPDATE 3-Immunomedics soars as lupus drug shows promise | Reuters

reuters.com — “* Positive Phase IIb results for UCB, Immunomedics drug * Treatment advantage of epratuzumab vs placebo 24.9 pct * Analysts say result promising but drug still high risk * Immunomedics shares upView full resource at reuters.com

  • View Related
  • Share

Most Recently Shared on August 27, 2009 at 8:25 am By:

reutersBenHir Ben Hirschler Health Communicator

UCB and Immunomedics clear Phase II lupus hurdle - but can they repeat Human Genome's Phase III success? http://tinyurl.com/kuyzw6

3 years ago...

Advertisement